Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients Without Previous Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e3182307e92
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

MA18.05 Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Development of Crizotinib, a Rationally Designed Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

Clinical Studies on Conformal Radiotherapy Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Second-Line Treatment of Non-Small Cell Lung Cancer

Tropical Journal of Pharmaceutical Research
PharmacologyPharmaceutical Science
2016English

Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2015English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2015English

Assessment of Clinical and Economic Effectiveness of Alectinib for Patients With ALK+ Non-Small Cell Lung Cancer Without Previous Experience of Targeted Therapy

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy